Last reviewed · How we verify
bOPV
bOPV is an oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis.
bOPV is an oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.
At a glance
| Generic name | bOPV |
|---|---|
| Also known as | Sanofi bOPV, bivalent Oral Polio Vaccine |
| Sponsor | Aga Khan University |
| Drug class | Live attenuated vaccine |
| Target | Poliovirus serotypes 1 and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
bOPV (bivalent oral polio vaccine) delivers weakened forms of poliovirus serotypes 1 and 3 orally, stimulating both intestinal mucosal immunity (IgA) and systemic humoral immunity (IgG). This dual immune response prevents infection and transmission of wild poliovirus in the gastrointestinal tract. The vaccine is part of global polio eradication initiatives, particularly in regions where type 2 poliovirus has been eliminated.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1 and 3
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines (PHASE1, PHASE2)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Immunogenicity nOPV2 With and Without bOPV (PHASE2)
- A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV CI brief — competitive landscape report
- bOPV updates RSS · CI watch RSS
- Aga Khan University portfolio CI